CN113773283B - Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof - Google Patents
Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof Download PDFInfo
- Publication number
- CN113773283B CN113773283B CN202111076698.1A CN202111076698A CN113773283B CN 113773283 B CN113773283 B CN 113773283B CN 202111076698 A CN202111076698 A CN 202111076698A CN 113773283 B CN113773283 B CN 113773283B
- Authority
- CN
- China
- Prior art keywords
- bis
- hydroxyphenyl
- hept
- trifluoroethyl
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oxo-bridged bicycloheptene sulfonamide compound containing a hydrophobic label and application thereof, belonging to the technical field of medicines. The compound of the invention comprises an OBHSA compound containing a adamantane tag and having a structure shown in a general formula I and an OBHSA compound containing a hydrophobic amino acid tag and having a structure shown in a general formula II, wherein n in the general formula 1 、n 2 Is a natural number of 1-60, and R is hydrophobic amino acid. The compound can degrade estrogen receptors and inhibit human breast cancer cells, and can be used for preparing medicines for targeted degradation of the estrogen receptors and anti-breast cancer medicines.
Description
Technical Field
The invention belongs to the technical field of medicines, and relates to a synthetic method of an oxido bridged bicycloheptene sulfonamide (OBHSA) compound containing amantadine and a hydrophobic amino acid label and application of the compound in an anti-breast cancer medicine.
Background
The targeted protein degradation strategy as an effective means for overcoming drug resistance receives more and more attention today when drug resistance becomes a key influencing factor for treating a plurality of diseases. Whether the resistance can be overcome by aiming at an important target Estrogen Receptor (ER) of the breast cancer also becomes a key judgment standard of the therapeutic effect of the target drug. There are two main strategies for targeted degradation of ER targets. One is that the compound displaces the protein helix exposing the hydrophobic pocket to recognition degradation by the ubiquitin-protease system, such as RAD1901. And the protein is degraded by ubiquitin labeling by direct binding of the ternary complex E3 ligand, PROTAC, to E3 ubiquitin ligase, such as ARV-471, which is advanced in phase I clinical studies.
However, each approach has its limitations, such as the first SERDs, which are generally requiredEntering the active pocket of the compound, certain binding affinity is required, the binding pocket of the estrogen receptor molecule is occupied, and the estrogen receptor molecule is changed, so that the hydrophobic pocket is exposed to exert the effect, the reasonable design requirement on the structure is very high, and a patterned design strategy is difficult to obtain. In the case of ProTAC technology, however, it has a high molecular weight, undesirable molecular rigidity and water solubility, and poor oral absorption and film permeability. Its poor pharmacokinetic properties are a major obstacle to its pharmacological properties. Therefore, it is important to discover new degradation strategies, compare the advantages and disadvantages of various strategies, and to investigate in-depth the mechanisms of action and biological activities of different types of molecules, such as reducing the size of the PROTAC, which is currently much larger than typical drugs (usually less than 500 Da), to increase cell permeability and potency. As shown in FIG. 1, there is a class of compounds similar to the strategy of PROTAC, where the target protein is recognized by the ubiquitin protease system by the addition of hydrophobic tags, which can be adamantane small molecules such as Compound 1 targeting tyrosine kinase and Compound 2 targeting androgen receptor AR, or single hydrophobic amino acid structures such as Boc 3 Arg, a successful example of which is compound 3 targeting glutathione S transferase. The molecules not only have good target protein degradation activity, but also have smaller molecular weight than that of the corresponding PROTAC, and the characteristic is also beneficial to the later-stage further research on the druggability.
Disclosure of Invention
In order to overcome the problems in the prior art, the compound of the present invention is designed by selecting an OBHSA compound having a degradation activity as a basic skeleton on a mother-nucleus structure, and then adding a hydrophobic tag to the compound by a side chain introduction method. The present invention contemplates that this tag may label the target protein by binding of OBHSA to the estrogen receptor, causing degradation of the target protein. In the selection of the hydrophobic tag, amantadine with a simple small molecular structure and Boc3Arg with a hydrophobic amino acid structure are respectively selected as the hydrophobic tags, and two types of molecules are designed and synthesized (figure 2). The invention hopes that the obtained compound not only can enhance the weaker ER degradation activity of the parent compound OBHSA, but also provides more reference for modeling design for estrogen receptor degradation.
The invention aims to provide an OBHSA compound containing a hydrophobic label, a preparation method of the compound and pharmaceutical application of the compound.
The purpose of the invention is realized by the following technical scheme:
the OBHSA compound containing the hydrophobic tag comprises the OBHSA compound containing the adamantane tag and the OBHSA compound containing the hydrophobic amino acid tag.
The adamantane tag-containing OBHSA compound has a structure shown in a general formula I:
in the general formula I, n 1 Is a natural number of 1 to 60, preferably 1, 3, 5, 7.
Preferably, the adamantane tag-containing OBHSA compound is selected from the following compounds:
n- ((3s, 5s, 7s) -adamantan-1-yl) -2- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) acetamide (20 a),
N- ((3s, 5s, 7s) -adamantan-1-yl) -4- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) butanamide (20 b),
N- ((3s, 5s, 7s) -adamantan-1-yl) -6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexanamide (20 c),
N- ((3s, 5s, 7s) -adamantan-1-yl) -8- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) octanamide (20 d).
The OBHSA compound containing the hydrophobic amino acid tag has a structure shown in a general formula II:
in the general formula II, n 2 Is a natural number of 1-60, preferably 3, 6; r is hydrophobic amino acid, such as D-Arg, L-Phe, L-Leu, L-Lys, L-Trp, etc.
Preferably, the hydrophobic amino acid tag-containing OBHSA compound is selected from the following compounds:
(2S) -2-amino-N- (3- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) propyl) -5-guanidinopentane amide derivatives (30 a),
(2R) -2-amino-N- (6- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) hexyl) -5-guanidinopentane amide derivatives (30 b),
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -1-oxo-3-phen-N-2-yl) carbamate (30 c),
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -1-oxo-3-phen-yn-2-yl) carbamate (30 d),
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxa [2.2.1] hept-5-en) -2-sulfonamido) phenoxy) propyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate (30 e),
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate (30 f),
Di-tert-butyl ((5S) -6- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -6-oxahexane-1, 5-diyl) dicarbamate (30 g),
Di-tert-butyl ((5R) -6- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -6-oxohexane-1, 5-diyl) dicarbamate (30 h),
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-en) -2-sulfonamido) phenoxy) propyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate (30 i),
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate (30 j).
The OBHSA compound containing the hydrophobic label can degrade estrogen receptors and inhibit human breast cancer cells, and can be used for preparing medicines for targeted degradation of estrogen receptors and anti-breast cancer medicines.
The drug for targeted degradation of estrogen receptors or the anti-breast cancer drug comprises the OBHSA compound containing the hydrophobic tag and one or more pharmaceutically acceptable carriers or excipients.
Compared with the prior art, the invention has the advantages and beneficial effects that:
PROTAC has the limitation of too large molecular weight, and a series of estrogen receptor down-regulators which are based on an OBHSA framework and mediated by hydrophobic tags, namely adamantane or hydrophobic amino acids, are synthesized by the invention, so that the obtained target compound has certain ER alpha and ER beta binding capacity. The introduction of the hydrophobic label can not only lead the compound to obtain MCF-7 cell inhibitory activity which is better than that of a parent compound (OBHSA), but also lead the compound to have good estrogen receptor down-regulation activity.
The hydrophobic label is introduced, the synthesis is simple and convenient, the yield is high, and the obtained target molecular weight is smaller than that of PROTAC and is better in cell membrane permeability and pharmacy. The introduction of the hydrophobic label as a successful technical means capable of selectively degrading the target protein has a more extensive application of the modeled design strategy compared with the traditional SERDs aiming at the reasonable design of the binding pocket, and is possible to obtain active compounds aiming at the target points which cannot be drugged. The addition of the two hydrophobic labels can be used as a modeling strategy in the future, and an idea and a reference are provided for the development of a novel estrogen receptor down-regulator.
Drawings
FIG. 1 is a representation of a hydrophobic tag mediated proteolytic degradation compound.
Figure 2 is an estrogen receptor down-regulator design mediated by a hydrophobic tag based on the OBHSA backbone.
FIG. 3 is a graph showing the results of example 17. (A) Western blot analysis of ER α in MCF-7 cells treated with 5 μ M of compounds Ful, 20a-d and 30 a; (B) comparison of the levels of ER α degradation by compounds 20a-d and 30 a; in the figure, C is a blank control.
Detailed Description
The preparation method of the hydrophobic tag-containing OBHSA compound comprises the following steps:
(1) Synthesis of 3, 4-bis (4-hydroxyphenyl) furan 9
The synthetic route is shown as the following reaction formula, and specifically comprises the following steps:
1) Synthesis of 2- (4-methoxyphenyl) -2-carbonylethyl-2- (4-methoxyphenyl) acetate (Compound 6)
Weighing 2-bromo-1- (4-methoxyphenyl) ethane-1-ketone 4 (1.5896g, 6.94mmol) and p-methoxyphenylacetic acid 5 (1.1532g, 6.94mmol) in a 50mL round-bottom flask, adding 25mL of anhydrous acetonitrile, slowly dropwise adding anhydrous triethylamine (702.3mg, 6.94mmol), continuing to react at room temperature for 12h, monitoring by TLC for reaction completion, concentrating under reduced pressure after the reaction is finished to remove acetonitrile and triethylamine, adding ethyl acetate to dissolve, and sequentially using dilute hydrochloric acid (2M, 30mL), saturated sodium bicarbonate (2X 30 mL) and saturated chlorinated hydrochloric acidWashing with sodium (30 mL), drying the organic layer with anhydrous sodium sulfate, filtering, and purifying by silica gel column chromatography (V) Methylene dichloride :V Methanol 1-400) to yield compound 6 as a yellow solid in 88% yield.
2) Synthesis of 3, 4-bis (4-methoxy-phenyl) furan-2-one (Compound 7)
Baking 25mL of two-necked flask and magneton at 105 deg.C for 15min, placing in a hot apparatus, performing anhydrous and anaerobic operation, adding compound 6 (786.2mg, 2.5 mmol) under Ar, adding 10mL of anhydrous DMSO, slowly adding 80% NaH (150.1mg, 5.0 mmol) dropwise, reacting at 25 deg.C for 3h, TLC monitoring reaction completion, adding 5mL of 2N HCl to quench reaction, extracting with ethyl acetate (3 × 25 mL), and collecting organic layer anhydrous NaSO 4 Drying and desolventizing under reduced pressure gave the crude product, which was purified on silica gel column (petroleum ether/ethyl acetate =9:1,v/v) to give 475.9mg (64.3% yield) of compound 7.
3) Synthesis of 3, 4-bis (4-hydroxy-phenylfuran) -2-one (Compound 8)
Baking 100mL of single-mouth bottle and magneton at 105 deg.C for 15min, placing in a hot device, adding compound 7 (1.345g, 4.56mmol) under Ar, adding 25mL of DCM, and adding BBr at-20 deg.C 3 (2.6 mL, 27.33mmol) for 12h, then the reaction was quenched with 10mL water, extracted with ethyl acetate (3X 20 mL), and saturated NaHCO 3 The solution (15 mL) was washed and the organic layer was anhydrous NaSO 4 Drying and desolventizing under reduced pressure gave the crude product, which was purified on silica gel column (petroleum ether/ethyl acetate = 7) to give 1.06g (yield 86.7%) of compound 8.
4) Synthesis of 3, 4-bis (4-hydroxy-phenyl) furan (Compound 9)
Baking 50mL single-mouth bottle and magneton at 105 deg.C for 15min, loading compound 8 (560mg, 1.98mmol) under Ar atmosphere in a hot apparatus, adding diisobutylaluminum hydride (DIBAL-H, 8mL, 7.93mmol) at-78 deg.C, reacting for 12H, and adding 4H 2 SO 4 The reaction was quenched, extracted with ethyl acetate (3X 25 mL), washed with saturated NaCl solution (30 mL), and the organic layer was dried over anhydrous NaSO 4 Drying, desolventizing under reduced pressure to obtain crude product, purifying with silica gel column (petroleum ether/ethyl acetate)Ester = 6) to yield 203.1mg (40.7% yield) of compound 9. 1 H NMR(400MHz,CDCl 3 ):δ7.41(s,2H),6.94(d,J＝8.4Hz,2H),6.87(d,J＝8.8Hz,2H).
(2) Synthesis of OBHSA derivatives with different length acid side chains
The synthesis route is shown as the following reaction formula, and the specific synthesis comprises the steps of stirring 4-methoxyaniline 10 and trifluoroacetic anhydride for 4 hours at room temperature to obtain a compound 11, reducing the compound 11 and borane dimethylsulfide at 60 ℃ to obtain a compound 12, and reacting the compound 12 and dichloroethane sulfonyl chloride at room temperature to obtain a compound 13, a compound 13 and BBr 3 Reacting at-20 ℃ to obtain a compound 14; under the alkaline condition, the compound 14 reacts with ethyl bromate (compounds 15a-d, n are respectively 1, 3, 5 and 7) with different lengths to obtain dienophiles 16a-d with ethyl bromate side chains, then the dienophiles 16a-d and the dihydroxyfuran compound 9 obtain corresponding end products through Diels-Alder reaction, and finally the obtained compounds are hydrolyzed by LiOH to obtain OBHSA derivatives 18a-d containing acidic side chains.
(3) Synthesis of the end product 20a-d with an adamantane Label
After obtaining the OBHSA derivatives 18a-d with different length acid side chains, the four compounds were condensed separately with commercially available amantadine molecules. The synthetic route is shown in the following reaction formula, DCC and HOBt are used as composite condensing agents, and under the action of DMF solvent, final products 20a-d with side chains of different lengths and containing adamantane labels are synthesized. Compared with PROTAC, the compound has the advantages of cheap and easily obtained raw materials, rapid synthesis and relatively simple and convenient operation.
(4) Synthesis of OBHSA derivative 25 with Boc amino side chain
The synthetic route is shown in the following reaction scheme, first, boc protection of amino group in 3-hydroxy propylamine 21 to obtain compound 22, followed by activation of hydroxy group of compound 22 with p-toluenesulfonyl chloride to obtain compound 23, then nucleophilic substitution of dienophile 14 and compound 23 to obtain dienophile derivative 24 with Boc amino side chain, and finally Diels-Alder reaction of compound 24 and dihydroxyfuran ring 9 to obtain OBHSA derivative 25 with Boc amino side chain.
(5) Synthesis of amino acid-based active ester derivatives 28a-e (for example, 26a arginine)
The synthetic route is shown in the following reaction formula, firstly, boc protection is carried out on the amino group of arginine 26a by using di-tert-butyl dicarbonate under alkaline condition to obtain an intermediate compound 27a, and then the carboxyl group of the compound 27a and N-hydroxysuccinimide react in the presence of EDC hydrochloride and DMAP to generate an active ester product 28a. Other reactive intermediates 28b-e were synthesized in a similar manner.
(6) With Boc 3 Synthesis of Arg side-chain OBHSA-like target product 30a
The synthetic route is shown in the following reaction scheme, after obtaining OBHSA derivative 25 with Boc protected amino side chain, under the action of hydrochloric acid, deprotection is carried out to obtain amino compound 29. The amino group of compound 29 was then reacted with arginine active ester 28a in THF as a solvent and TEA as a base to form a compound with Boc 3 OBHSA target product 30a of Arg side chain.
(7) Synthesis of OBHSA target product 30b-j with amino acid side chain
In a manner similar to the synthesis of compound 30a, after obtaining the OBHSA derivative 25 having a Boc-protected amino side chain, it is deprotected under the action of hydrochloric acid to obtain an amino compound 29. Then, the amino group of compound 29 and the amino acid active ester products 28b-f are reacted under THF as a solvent and TEA as a base to form OBHSA target products 30b-30j with Boc amino acid side chains.
The following examples are intended to further illustrate the invention but should not be construed as limiting it. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
Example 1: preparation of (2S) -2-amino-N- (3- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) propyl) -5-guanidinopentaneamide derivative (30 a):
compound 29 (74.62mg, 0.126mmol) and compound 28a (85.95mg, 0.15mmol) were placed in a 25mL one-neck flask, dissolved in 2mL THF, triethylamine (15.21mg, 0.15mmol) was added, after 2h of reaction, TLC confirmed that the reaction was complete, extracted with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-30) to give 108mg of compound 30a as a yellow solid in a yield of 77%. 1 H NMR(400MHz,MeOD-d 6 )δ7.19(d,J＝8.8Hz,2H),7.12(t,J＝8.4Hz,4H),6.78(t,J＝9.1Hz,4H),6.69(d,J＝8.7Hz,2H),5.45(s,1H),5.29(d,J＝4.2Hz,1H),4.40(q,J＝8.4Hz,2H),3.97(t,J＝6.1Hz,3H),3.84(td,J＝13.8,6.9Hz,2H),3.44-3.34(m,3H),2.21(dt,J＝11.8,4.3Hz,1H),2.01(dd,J＝7.0,4.5Hz,1H),1.99-1.92(m,2H),1.73-1.67(m,1H),1.69-1.57(m,3H),1.51(s,9H),1.45(s,9H),1.39(s,9H).HRMS(ESI)calcd for C 50 H 65 F 3 N 6 O 13 S[M+Na] + ,1069.4175；found 1069.4168.
Example 2: preparation of (2R) -2-amino-N- (6- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) hexyl) -5-guanidinopentaneamide derivative (30 b):
compound 29 (40mg, 0.068mmol) and compound 28b (57.3mg, 0.10mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (8.2mg, 0.08mmol) was added thereto, the reaction was carried out for 2 hours, after completion of the reaction was confirmed by TLC, extraction was carried out with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and the mixture was separated and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 47mg of compound 30b as a pale yellow solid in a yield of 50%. Nuclear magnetic hydrogen spectrum of point 1: 1 H NMR(400MHz,Acetone-d 6 )δ7.55(s,1H),7.33(d,J＝2.2Hz,1H),7.30(d,J＝2.2Hz,1H),7.26(d,J＝4.3Hz,4H),7.20(dd,J＝8.5,4.3Hz,5H),6.88(d,J＝1.2Hz,1H),6.86(d,J＝1.2Hz,1H),6.83(d,J＝2.7Hz,1H),6.81(s,2H),6.79(s,1H),6.13(s,1H),5.53(s,1H),5.35(d,J＝3.9Hz,1H),4.58–4.47(m,2H),4.34(t,J＝6.0Hz,1H),3.94(d,J＝6.2Hz,2H),3.54(dd,J＝12.6,4.3Hz,1H),3.45–3.35(m,2H),3.14(dd,J＝13.7,6.1Hz,1H),2.95(dd,J＝13.6,8.3Hz,1H),2.24(dd,J＝13.7,6.0Hz,1H),2.10(d,J＝4.9Hz,1H),1.98-1.86(m,2H),1.39(d,J＝19.8Hz,2H),1.33(s,9H).HRMS(ESI)calcd for C 43 H 46 F 3 N 3 O 9 S[M+Na] + ,860.2799；found 860.2789.
example 3: preparation of tert-butyl ((2S) -1- ((3- (4- ((1r, 4r) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -1-oxo-3-phen-inph-2-yl) carbamate (30 c):
compound 29 (40mg, 0.068mmol) and compound 28c (32mg, 0.10mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (8.2mg, 0.08mmol) was added thereto, the reaction was carried out for 2 hours, after completion of the reaction was confirmed by TLC, extraction was carried out with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and separation and purification were carried out by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15). Nuclear magnetic hydrogen spectrum of point 1: 1 H NMR(400MHz,Acetone-d 6 )δ7.55(s,1H),7.33(d,J＝2.2Hz,1H),7.30(d,J＝2.2Hz,1H),7.26(d,J＝4.3Hz,4H),7.20(dd,J＝8.5,4.3Hz,5H),6.88(d,J＝1.2Hz,1H),6.86(d,J＝1.2Hz,1H),6.83(d,J＝2.7Hz,1H),6.81(s,2H),6.79(s,1H),6.13(s,1H),5.53(s,1H),5.35(d,J＝3.9Hz,1H),4.58–4.47(m,2H),4.34(t,J＝6.0Hz,1H),3.94(d,J＝6.2Hz,2H),3.54(dd,J＝12.6,4.3Hz,1H),3.45–3.35(m,2H),3.14(dd,J＝13.7,6.1Hz,1H),2.95(dd,J＝13.6,8.3Hz,1H),2.24(dd,J＝13.7,6.0Hz,1H),2.10(d,J＝4.9Hz,1H),1.98-1.86(m,2H),1.39(d,J＝19.8Hz,2H),1.33(s,9H).HRMS(ESI)calcd for C 43 H 46 F 3 N 3 O 9 S[M+Na] + ,860.2799；found 860.2789.
example 4: preparation of tert-butyl ((2R) -1- ((6- (4- ((1r, 4r) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -1-oxo-3-phen-inp-2-yl) carbamate (30 d):
compound 29 (40mg, 0.068mmol) and compound 28c (68mg, 0.1699 mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (8.2mg, 0.08mmol) was added thereto, the reaction was carried out for 2 hours, after completion of the reaction was confirmed by TLC, extraction was carried out with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and the mixture was purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15). 1 H NMR(400MHz,CDCl 3 )δ7.30–7.24(m,2H),7.23–7.19(m,2H),7.17(d,J＝6.1Hz,2H),7.15–7.08(m,5H),6.82(d,J＝8.0Hz,2H),6.74(dd,J＝16.8,8.0Hz,4H),6.40(s,1H),5.51(s,1H),5.38(s,1H),5.31(s,1H),4.29(d,J＝26.7Hz,2H),3.86(s,2H),3.40(s,1H),3.22(s,1H),3.11(s,1H),3.00(d,J＝14.1Hz,2H),2.38(s,1H),2.00(s,1H),1.68(s,2H),1.42(s,1H),1.39(s,9H),1.31(s,3H),1.20(s,2H).HRMS(ESI)calcd for C 46 H 52 F 3 N 3 O 9 S[M+Na] + ,902.3268；found 902.3264.
Example 5: preparation of tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxa [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate (30 e):
compound 29 (80mg, 0.135mmol) and compound 28d (44.4mg, 0.135mmol) were placed in a 25mL single-neck flask, dissolved in 2mL of THF, triethylamine (16.4mg, 0.16mmol) was added, after 2h of reaction, TLC confirmed the completion of the reaction, extracted with ethyl acetate, the organic phase was concentrated and spun dry, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-30). 1 H NMR(400MHz,Acetone-d 6 )δ7.59(s,1H),7.30(dd,J＝8.4,3.1Hz,2H),7.26(d,J＝4.3Hz,1H),7.19(d,J＝8.6Hz,4H),6.87(d,J＝8.5Hz,2H),6.83(dd,J＝9.0,2.5Hz,2H),6.79(d,J＝8.6Hz,2H),6.14(s,1H),5.50(s,1H),5.35(d,J＝4.3Hz,1H),4.51(dd,J＝10.0,7.7Hz,2H),4.17–3.98(m,2H),3.52(dd,J＝7.9,3.9Hz,1H),3.42(d,J＝6.1Hz,2H),2.24(dd,J＝11.9,4.4Hz,1H),2.15(dd,J＝39.0,9.3Hz,1H),1.97(dd,J＝13.6,5.5Hz,2H),1.71(dt,J＝13.2,6.5Hz,1H),1.63–1.52(m,2H),1.39(s,9H),1.33(d,J＝2.9Hz,2H),1.30(s,2H),1.28(d,J＝1.8Hz,1H),0.91(t,J＝6.2Hz,6H).HRMS(ESI)calcd for C 40 H 48 F 3 N 3 O 9 S[M+Na] + ,826.2956；
found 826.2950.
Example 6: preparation of tert-butyl ((2R) -1- ((6- (4- ((1r, 4r) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate (30 f):
compound 29 (80mg, 0.127mmol) and compound 28d (44.4mg, 0.135mmol) were placed in a 25mL single vial, dissolved in 2mL of THF, triethylamine (16.0mg, 0.16mmol) was added, after 2h of reaction, TLC confirmed the completion of the reaction, and extracted with ethyl acetate, the organic phase was concentrated to dryness, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-20) to give 85.6mg of a pale yellow compound 30f in 80% yield. 1 H NMR(400MHz,CDCl 3 )δ8.33(s,1H),7.11–7.03(m,6H),6.82(d,J＝7.3Hz,2H),6.73(d,J＝8.5Hz,2H),6.67(dd,J＝8.9,3.4Hz,2H),5.45(s,1H),5.30(d,J＝6.9Hz,1H),5.10(s,1H),4.27(dd,J＝13.9,7.0Hz,2H),4.07(s,1H),3.86(t,J＝5.8Hz,2H),3.36(d,J＝5.9Hz,1H),3.25(dd,J＝13.5,7.0Hz,2H),2.39(dd,J＝12.1,8.0Hz,1H),2.06–1.82(m,3H),1.74–1.66(m,2H),1.62(dd,J＝14.9,7.2Hz,2H),1.54–1.46(m,2H),1.41(s,9H),1.34(d,J＝6.2Hz,2H),0.89(t,J＝5.9Hz,6H).HRMS(ESI)calcd for C 43 H 54 F 3 N 3 O 9 S[M+Na] + ,868.3425；found 868.3421.
Example 7: preparation of di-tert-butyl ((5S) -6- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -6-oxahexane-1, 5-diyl) dicarbamate (30 g):
compound 29 (45mg, 0.076 mmol) and compound 28e (56.3mg, 0.127mmol) were placed in a 25mL single-neck flask, dissolved in 2mL of THF, triethylamine (9.3mg, 0.09mmol) was added, after 2 hours of reaction, TLC confirmed the completion of the reaction, and extracted with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 36.5mg of a pale yellow solid compound 30g with a yield of 52%. 1 H NMR(400MHz,Acetone-d 6 )δ8.99(s,1H),8.73(s,1H),7.62(s,1H),7.30(d,J＝7.7Hz,3H),7.19(d,J＝8.7Hz,5H),6.87(d,J＝8.6Hz,2H),6.84(dd,J＝9.0,2.3Hz,2H),6.79(d,J＝8.6Hz,2H),6.17(d,J＝6.9Hz,1H),6.02(s,1H),5.51(s,1H),5.36(d,J＝4.2Hz,1H),4.52(d,J＝8.5Hz,3H),3.53(dd,J＝7.4,3.8Hz,1H),3.43(d,J＝5.7Hz,3H),3.10(s,5H),3.06(dd,J＝12.9,6.6Hz,4H),2.23(dd,J＝11.9,4.5Hz,1H),2.10(d,J＝7.8Hz,1H),1.97(d,J＝5.9Hz,2H),1.79(dd,J＝11.8,7.3Hz,1H),1.68(dd,J＝17.8,9.0Hz,2H),1.54–1.43(m,5H),1.41(s,11H),1.39(s,10H).
Example 8: preparation of di-tert-butyl ((5R) -6- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -6-oxohexane-1, 5-diyl) dicarbamate (30 h):
compound 29 (60mg, 0.10mmol) and compound 28e (50.5mg, 0.11mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (11.52mg, 0.11mmol) was added, reaction was carried out for 2 hours, completion of the reaction was confirmed by TLC, extraction was carried out with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and separation and purification were carried out by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 47.2mg of a pale yellow solid compound 30h with a yield of 52%. 1 H NMR(400MHz,Acetone-d 6 )δ8.91(s,1H),8.68(s,1H),7.32(d,J＝8.9Hz,2H),7.20(dd,J＝8.5,6.6Hz,4H),6.85(dd,J＝8.6,7.5Hz,4H),6.79(d,J＝8.6Hz,2H),6.17(d,J＝7.6Hz,1H),6.00(s,1H),5.53(s,1H),5.35(d,J＝4.0Hz,1H),4.52(q,J＝8.4Hz,2H),4.08–3.92(m,4H),3.52(dd,J＝9.5,5.0Hz,1H),3.26(dd,J＝13.2,6.6Hz,2H),3.06(dd,J＝12.8,6.5Hz,2H),2.31–2.21(m,1H),2.21–2.09(m,1H),1.84–1.73(m,4H),1.65(ddd,J＝18.1,9.3,4.9Hz,2H),1.57–1.46(m,6H),1.41(s,9H),1.41(s,9H),1.30(s,6H).HRMS(ESI)calcd for C 48 H 63 F 3 N 4 O 11 S[M+Na] + ,969.4027；found 969.3961.
Example 9: preparation of tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate (30 i):
compound 29 (40mg, 0.068mmol) and compound 28f (54mg, 0.134mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (8.2mg, 0.08mmol) was added thereto, the reaction was carried out for 2 hours, after completion of the reaction was confirmed by TLC, extraction was carried out with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and the mixture was separated and purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 47.5mg of 30i as a white solid in 80% yield. 1 H NMR(400MHz,MeOD)δ7.56(d,J＝7.8Hz,1H),7.30(d,J＝8.1Hz,1H),7.18(dd,J＝8.6,6.8Hz,2H),7.12(dd,J＝8.1,4.0Hz,4H),7.06(d,J＝5.8Hz,2H),6.98(d,J＝7.5Hz,1H),6.76(d,J＝8.6Hz,2H),6.72–6.66(m,4H),5.45(s,1H),5.29(d,J＝4.1Hz,1H),4.40(q,J＝8.3Hz,2H),4.27(t,J＝9.7Hz,1H),3.64(d,J＝9.1Hz,2H),3.45–3.40(m,1H),3.16(dd,J＝9.3,5.3Hz,2H),2.20(dd,J＝9.5,5.2Hz,1H),1.99(dd,J＝12.2,8.6Hz,1H),1.79–1.66(m,2H),1.49(dd,J＝17.6,10.5Hz,2H),1.36(s,9H).
Example 10: preparation of tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate (30 j):
compound 29 (40mg, 0.068mmol) and compound 28f (32mg, 0.10mmol) were placed in a 25mL single-necked flask, dissolved in 2mL of THF, triethylamine (8.2mg, 0.08mmol) was added, the reaction was allowed to proceed for 2 hours, after completion of the reaction was confirmed by TLC, extraction was performed with ethyl acetate, the organic phase was concentrated and dried, dried over anhydrous sodium sulfate, and the mixture was purified by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 39.5mg of compound 30j as a white solid in a yield of 68%. 1 H NMR(400MHz,Acetone-d 6 )δ10.12(s,1H),9.00(s,1H),8.80(s,1H),7.62(d,J＝7.8Hz,1H),7.37(d,J＝8.1Hz,1H),7.30(d,J＝8.9Hz,2H),7.20(s,1H),7.17(d,J＝8.8Hz,4H),7.08(t,J＝7.4Hz,1H),7.00(t,J＝7.5Hz,1H),6.84(t,J＝8.7Hz,4H),6.78(d,J＝8.6Hz,2H),5.98(d,J＝7.6Hz,1H),5.52(s,1H),5.33(d,J＝4.2Hz,1H),4.50(q,J＝8.6Hz,2H),4.38(d,J＝7.0Hz,1H),3.94(t,J＝6.4Hz,2H),3.52(dd,J＝9.2,3.4Hz,1H),3.22(d,J＝6.2Hz,1H),3.15(d,J＝7.0Hz,1H),2.21(dd,J＝8.3,3.8Hz,1H),2.12(dd,J＝35.0,5.8Hz,1H),1.71(dd,J＝13.9,6.8Hz,2H),1.45–1.38(m,4H),1.35(s,9H),1.28(s,4H).
N- ((3s, 5s, 7s) -adamantan-1-yl) -3- (4- ((((((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [ 2.2.1)]Hept-5-ene) -2-sulfonylamino) phenoxy) amide end-products 20a-d synthesis: under the protection of Ar, the compounds 18a-d, DCC and HOBT were respectively added into a double-mouth bottle and dissolved in DMF. After 10min, adding amantadine, stirring at room temperature for about 4h, TLC confirming reaction completion, adding water for quenching, EA extracting, washing organic phase with supersaturated sodium bicarbonate for multiple times, concentrating, spin drying, and separating and purifying by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol ＝200:1-15:1)，The final products 20a-d were obtained (65% -74% yield).
Example 11: preparation of N- ((3s, 5s, 7s) -adamantan-1-yl) -2- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) acetamide (20 a):
under Ar protection, compound 18a (100mg, 0.17mmol), DCC (105mg, 0.51mmol) and HOBT (31mg, 0.20mmol) were added to each flask and dissolved in DMF. After 10min, adding amantadine (38mg, 0.25mmol), stirring at room temperature for about 4h, TLC confirming reaction completion, adding water for quenching, EA extracting, washing organic phase with supersaturated sodium bicarbonate for multiple times, concentrating, spin drying, and separating and purifying by silica gel column chromatography (eluent ratio v is v) Methylene dichloride /v Methanol 1-15) to yield 125mg of yellow solid 20a in 68% yield. 1 H NMR(400MHz,MeOD-d 6 )δ7.27(d,J＝9.0Hz,2H),7.13(t,J＝8.8Hz,4H),6.88(d,J＝9.0Hz,2H),6.78(d,J＝8.6Hz,2H),6.70(d,J＝8.7Hz,2H),5.46(d,J＝0.7Hz,1H),5.29(d,J＝3.9Hz,1H),4.48–4.38(m,4H),3.46(dd,J＝8.4,4.4Hz,1H),2.24–2.20(m,1H),2.18(t,J＝4.5Hz,1H),2.03(s,9H),1.72(d,J＝13.3Hz,6H).
Example 12: preparation of N- ((3s, 5s,7 s) -adamantan-1-yl) -4- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) butyramide (20 b):
under the protection of Ar, compound 18b (100mg, 0.16mmol), DCC (100mg, 0.48mmol) and HOBT (29mg, 0.19mmol) are respectively added into a double-mouth bottle and dissolved by DMF. After 10min, adding amantadine (37mg, 0.24mmol), stirring at room temperature for about 4h, TLC confirming reaction completion, adding water for quenching, EA extracting, washing organic phase with supersaturated sodium bicarbonate for multiple timesConcentrating, spin drying, separating and purifying by silica gel column chromatography (eluent ratio v) Methylene dichloride /v Methanol 1-15) to give 125mg of 20b as a yellow solid in 74% yield. 1 H NMR(400MHz,MeOD-d 6 )δ7.20(dd,J＝9.0,2.3Hz,2H),7.14(t,J＝9.3Hz,4H),6.81–6.76(m,4H),6.71(d,J＝8.7Hz,2H),5.46(s,1H),5.30(d,J＝4.0Hz,1H),4.42(q,J＝8.5Hz,2H),4.02–3.93(m,2H),3.44(dt,J＝8.6,4.4Hz,1H),2.29–2.15(m,1H),2.15–2.05(m,1H),1.98(s,9H),1.83(dd,J＝28.9,13.6Hz,2H),1.68(s,6H),1.40–1.34(m,2H).
Example 13: preparation of N- ((3s, 5s, 7s) -adamantan-1-yl) -6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexanamide (20 c):
under the protection of Ar, compound 18c (100mg, 0.15mmol), DCC (96mg, 0.46mmol) and HOBT (28mg, 0.19mmol) were added to a two-necked flask and dissolved in DMF. After 10min, adding amantadine (35mg, 0.23mmol), stirring at room temperature for about 4h, TLC confirming reaction completion, adding water for quenching, EA extracting, washing organic phase with supersaturated sodium bicarbonate for multiple times, concentrating, spin drying, and separating and purifying by silica gel column chromatography (eluent ratio v is v) Methylene dichloride /v Methanol 1-30). 1 H NMR(400MHz,MeOD-d 6 )δ7.27(d,J＝9.0Hz,2H),7.13(t,J＝8.8Hz,4H),6.88(d,J＝9.0Hz,2H),6.78(d,J＝8.6Hz,2H),6.70(d,J＝8.7Hz,2H),5.46(d,J＝0.7Hz,1H),5.29(d,J＝3.9Hz,1H),4.48–4.38(m,4H),3.46(dd,J＝8.4,4.4Hz,1H),2.24–2.20(m,1H),2.18(t,J＝4.5Hz,1H),2.03(s,9H),1.72(d,J＝13.3Hz,6H).
Example 14: preparation of N- ((3s, 5s, 7s) -adamantan-1-yl) -8- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) octanamide (20 d):
under the protection of Ar, compound 18d (100mg, 0.15mmol), DCC (92mg, 0.44mmol) and HOBT (27mg, 0.18mmol) were added to a double-necked flask and dissolved in DMF. After 10min, adding amantadine (34mg, 0.22mmol), stirring at room temperature for about 4h, TLC confirming reaction completion, adding water for quenching, EA extracting, washing organic phase with supersaturated sodium bicarbonate for multiple times, concentrating, spin drying, and separating and purifying by silica gel column chromatography (eluent ratio v is Methylene dichloride /v Methanol 1-30). 1 H NMR(400MHz,MeOD-d 6 )δ7.20(dd,J＝9.0,2.3Hz,2H),7.14(t,J＝9.3Hz,4H),6.81–6.76(m,4H),6.71(d,J＝8.7Hz,2H),5.46(s,1H),5.30(d,J＝4.0Hz,1H),4.42(q,J＝8.5Hz,2H),4.02–3.93(m,2H),3.44(dt,J＝8.6,4.4Hz,1H),2.29–2.15(m,1H),2.15–2.05(m,1H),1.98(s,9H),1.83(dd,J＝28.9,13.6Hz,2H),1.68(s,6H),1.40–1.34(m,2H).
Example 15: relative affinity assay for Compounds
The affinity of the target compound for ER alpha and ER beta is determined by fluorescence polarization method, and the affinity of the compound is endogenous E 2 Relative value of affinity, set E 2 The value of affinity for the receptor RBA =100%. To a 384 well plate, 20. Mu.L of a potassium phosphate buffer composed of 0.8. Mu.MER. Alpha. Or ER. Beta. Protein, 150nM fluorescent ligand and 2.4. Mu.g bovine immunoglobulin was added, and then 20. Mu.L of a target compound solution was added, with a compound concentration gradient of 3.16X 10 -4 M、1×10 -4 M、3.16×10 -5 M、1×10 -5 M、3.16×10 -6 M、1×10 -6 M、3.16×10 -7 M、1×10 -7 M、3.16×10 -8 M、1×10 -8 M、3.16×10 -9 And M. Placing in dark place at room temperature for 2 hr, reading on a microplate reader, selecting 485nm wavelength as main wavelength and 528nm wavelength as reference wavelength, analyzing the experimental result, and determining receptor affinity RBA = test substance K according to formula i Estradiol K i The RBA (relative binding affinity) value of each compound was calculated by x 100, and the results are shown inTable 1.
TABLE 1 Relative Binding Affinities (RBA) of target compounds 20a-d and target compounds 30a-j for ER α and ER β a
a Relative binding affinity was tested by fluorescence polarization, expressed as IC 50 estradiol/IC 50 Compound x 100 ± standard deviation (binding affinity of estradiol is set as 100%).
This example tested the 14 compounds for binding affinity to era and the results are listed in table 1. In compounds 20a-d and 30a-j, either the introduction of the adamantane side chain or Boc 3 The introduction of Arg side chain can obtain the final product with certain binding force to ER alpha. Wherein, contains Boc 3 The RBA value for era for compound 30a of the Arg side chain reached 3.21, which may be related to the correct positioning of the compound in the era pocket, with the side chain moiety exposed outside the pocket. Introduction of other hydrophobic tags, e.g. L-Boc 3 -Arg、L-Boc-Phe、L-Boc-Leu、L-Boc 2 -Lys, L-Boc-Trp, all have a relatively good affinity, with 30j having the highest RBA for ER α of 9.76.
In addition, the obtained compounds 20a-d and 30a-j can keep the characteristic that the parent compound OBHSA is used as an ER ligand, and lay a foundation for the compounds to exert the biological effects.
Example 16: cell viability assay
MCF-7 cells were cultured in DMEM liquid medium with phenol red containing 10% fetal bovine serum. When the cell density reached 80% to 90%, the cells were digested and the cell suspension was plated into 96-well cell culture plates with phenol red-free DMEM medium containing 10% fbs. After the cells were completely attached to the wall, the stock culture was discarded, and 100. Mu.L of a fresh solution of the compound prepared in 10% FBS-containing DMEM medium, the compound, was added to each wellConcentration gradient of 1 × 10 -7.5 M、1×10 -7 M、1×10 -6.5 M、1×10 -6 M、1×10 - 5.5 M、1×10 -5 M、1×10 -4.5 M、1×10 -4 And M. After 4 days of drug treatment, the plates are removed, the culture broth aspirated, 100. Mu.L of CCK8 working solution is added to each well, the mixture is incubated at 37 ℃ with 5% CO 2 Incubate in incubator for 1.5-2 hours. Reading the plate on a microplate reader, selecting the wavelength of 450nm as the reference wavelength, analyzing the experimental result, and calculating IC 50 The results are shown in Table 2.
TABLE 2 Effect of target Compounds 20a-d and 30a-j on Breast cancer cell MCF-7 cell viability
a IC 50 Is the mean ± standard deviation of at least three independent experiments.
This example evaluated the effect of these 14 compounds on MCF-7 cell viability. Compounds 20a-d with adamantane side chains all had some effect on MCF-7 cell viability, whereas, of these, compounds 20a and 20b had the greatest effect, both compounds having IC' s 50 Values were both around 21 and 40 nM. While the inhibition of MCF-7 cell viability by the adamantane bearing OBHSA derivatives 20c and 20d was gradually diminished with further increase in the compound side chain length, indicating that the side chain length has a critical effect on the activity when a hydrophobic tag was introduced.
When Boc is reacted 3 The Arg label is introduced into the OBHSA side chain to obtain a target product 30a, and the compound 30a also has good cell inhibition activity on MCF-7 and IC thereof 50 The value was 16nM, which indicates Boc 3 Arg can also be used as an excellent group for the modification of a targeting ER compound to obtain a sprout head molecule with better activity for inhibiting MCF-7 cell viability. By testing the hydrophobic amino groups of different side chainsThe cell activity of acid, found at chain length of 6, was generally superior to that of 3, where R is L-Boc 2 -Lys and L-Boc-Trp, the cellular activity of the compounds was at 4.17 and 5.77nM.
Example 17: ER degradation Activity assay
In order to demonstrate the capability of the synthesized OBHSA derivatives with hydrophobic tags to degrade estrogen receptors, the influence of chain length and different types of hydrophobic tags on the protein degradation activity was analyzed. This example treated MCF-7 24h with fulvestrant (Ful) and five compounds 20a-d, 30a (5. Mu.M) and then extracted all proteins and analysed by Western immunoblotting for the effect of compounds 20a-d and also 30a on degradation of ER α and compared with fulvestrant. The results are shown in FIG. 3.
As can be seen from fig. 3, this series of compounds has good ER α downregulation activity, wherein compounds 20a, 20b and 30a and fulvestrant all completely degrade ER α at 5 μ M. In addition, even though compound 20d had poor inhibitory activity on MCF-7 cell viability, it was able to degrade most ER α at 5 μ M. From the results, it can also be seen that the degradation activity of compounds 20a-d on ER α is also related to the length of its side chain, and that the degradation activity of the target product decreases as the chain length increases to a certain length. Therefore, the appropriate side chain length is also important for the ER α degradation activity. By comparing adamantyl containing tags with Boc 3 Arg-tagged two classes of compounds, the introduction of Boc was found 3 The Arg tag also allows the compound to obtain better ER alpha degrading activity, and the compound 30a can completely degrade ER alpha at the same concentration.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (9)
1. An oxo-bridged bicycloheptene sulfonamide compound containing a hydrophobic label is characterized in that: comprises an oxido bicycloheptene sulfonamide compound containing a diamidine label and an oxido bicycloheptene sulfonamide compound containing a hydrophobic amino acid label:
the oxo-bridged bicycloheptene sulfonamide compound containing the amantadine label has a structure shown in a general formula I:
in the general formula I, n 1 Is a natural number of 1-7;
the oxo-bridged bicycloheptene sulfonamide compound containing the hydrophobic amino acid label has a structure shown as a general formula II:
in the general formula II, n 2 Is a natural number of 1-6; r is hydrophobic amino acid.
2. The hydrophobic tag containing oxido-bicycloheptene sulfonamide compound of claim 1, wherein: n is a radical of an alkyl radical 1 Is 1, 3, 5, 7,n 2 Are 3 and 6.
3. The hydrophobic tag containing oxido-bicycloheptene sulfonamide compound of claim 1, wherein: the hydrophobic amino acid comprises D-Arg, L-Phe, L-Leu, L-Lys and L-Trp.
4. The hydrophobic tag containing oxido-bicycloheptene sulfonamide compound of claim 1, wherein:
the oxo-bridged bicycloheptene sulfonamide compound containing the amantadine label is selected from the following compounds:
n- ((3s, 5s, 7s) -adamantan-1-yl) -2- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) acetamide,
N- ((3s, 5s, 7s) -adamantan-1-yl) -4- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) butyramide,
N- ((3s, 5s, 7s) -adamantan-1-yl) -6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexanamide,
N- ((3s, 5s, 7s) -adamantan-1-yl) -8- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) octanamide;
the oxo-bridged bicycloheptene sulfonamide compound containing the hydrophobic amino acid label is selected from the following compounds:
(2S) -2-amino-N- (3- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) propyl) -5-guanidinopentaneamide derivatives,
(2R) -2-amino-N- (6- (4- ((5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7) - [2.2.1] hept-5-ene) -2-sulfonamide (phenoxy) hexyl) -5-guanidinopentaneamide derivatives,
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -1-oxo-3-phen-prop-2-yl) carbamate,
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -1-oxo-3-phend-en-2-yl) carbamate,
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxa [2.2.1] hept-5-en) -2-sulfonamido) phenoxy) propyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate,
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -4-methyl-1-oxopentan-2-yl) carbamate,
Di-tert-butyl ((5S) -6- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -6-oxahexane-1, 5-diyl) dicarbamate,
Di-tert-butyl ((5R) -6- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -6-oxohexane-1, 5-diyl) dicarbamate,
Tert-butyl ((2S) -1- ((3- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) propyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate,
Tert-butyl ((2R) -1- ((6- (4- ((1R, 4R) -5, 6-bis (4-hydroxyphenyl) -N- (2, 2-trifluoroethyl) -7-oxabicyclo [2.2.1] hept-5-ene) -2-sulfonamido) phenoxy) hexyl) amino) -3- (1H-indol-2-yl) -1-oxopropan-2-yl) carbamate.
5. Use of the oxo-bridged bicycloheptene sulfonamides containing hydrophobic tags as claimed in any one of claims 1 to 4 in the manufacture of a medicament for the treatment of breast cancer.
6. Use of the oxido-bicycloheptenesulfonamide compounds containing hydrophobic tags according to any one of claims 1 to 4 for the preparation of a medicament for the targeted degradation of estrogen receptors.
7. An anti-breast cancer drug, which is characterized in that: a compound of the oxido-bicycloheptene sulfonamide type containing a hydrophobic tag of any of claims 1 to 4.
8. A drug for targeted degradation of an estrogen receptor, comprising: a compound comprising the hydrophobic tag-containing oxido-bicycloheptenesulfonamide of any one of claims 1 to 4.
9. The medicament according to claim 7 or 8, characterized in that: comprising one or more pharmaceutically acceptable carriers or excipients of a compound according to any one of claims 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111076698.1A CN113773283B (en) | 2021-09-14 | 2021-09-14 | Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111076698.1A CN113773283B (en) | 2021-09-14 | 2021-09-14 | Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113773283A CN113773283A (en) | 2021-12-10 |
| CN113773283B true CN113773283B (en) | 2023-04-07 |
Family
ID=78843855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111076698.1A Active CN113773283B (en) | 2021-09-14 | 2021-09-14 | Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113773283B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115557965B (en) * | 2022-09-28 | 2024-03-19 | 武汉大学 | PROTACs compound for dual targeting degradation of estrogen receptor alpha and aromatizing enzyme and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942595A (en) * | 2019-01-28 | 2019-06-28 | 武汉大学 | Oxygen bridge containing different functionalities side-chain structure is bicyclic-[2.2.1]-heptan vinyl compound and its preparation and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864127B (en) * | 2018-08-02 | 2020-06-23 | 武汉大学 | Oxidobicycloheptene sulfonamide compound with different alkyl chain lengths as well as preparation method and application thereof |
| CN110759897A (en) * | 2019-11-07 | 2020-02-07 | 郑州大学 | Triazole-containing hydrophobic adamantane type selective androgen receptor degradation agent and preparation method thereof |
| CN111704648B (en) * | 2020-06-23 | 2022-02-15 | 武汉大学 | Proteolysis targeting chimera compound with oxido bicycloheptene compound as estrogen receptor ligand, preparation method and application |
-
2021
- 2021-09-14 CN CN202111076698.1A patent/CN113773283B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942595A (en) * | 2019-01-28 | 2019-06-28 | 武汉大学 | Oxygen bridge containing different functionalities side-chain structure is bicyclic-[2.2.1]-heptan vinyl compound and its preparation and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113773283A (en) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101573351B (en) | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor | |
| CN108395443B (en) | Cyclic compounds inhibiting programmed death receptor ligand 1 and uses thereof | |
| WO2016192586A1 (en) | Deuterium-substituted dehydrophenylahistin-like compound, preparation method thereof and use in preparation of antitumor drug | |
| EP3495354A1 (en) | Ido1 inhibitor and preparation method and application thereof | |
| CN113698401B (en) | Beta-elemene macrocyclic derivatives, preparation method and application thereof | |
| CN106749513A (en) | Bifunctional molecule and its preparation and application based on the induction BET degradeds of VHL parts | |
| CN113773283B (en) | Oxidobicycloheptene sulfonamide compound containing hydrophobic label and application thereof | |
| CN104327097A (en) | Triazole derivatives of rapamycin and application | |
| CN115368306B (en) | HDAC inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | |
| CN107266466A (en) | The application of scutellarin biotinylated probe and correlation PKM2 kinase inhibitors | |
| CN114805269B (en) | Eriocalyxin B derivative and application thereof in preparation of antitumor drugs | |
| CN116120239A (en) | Aromatic six-membered cycloimidazole derivative, and preparation method and application thereof | |
| CN113461563B (en) | NQO1 activated 6-diazo-5-oxo-L-norleucine prodrug and preparation method and application thereof | |
| CN115536567A (en) | Beta-elemene derivative containing photoaffinity group diazirine, preparation method thereof and application of beta-elemene derivative as photoaffinity molecular probe | |
| CN104530081A (en) | Nitrogenous heterocyclic derivative of rapamycin and application | |
| CN110627615B (en) | Beta-elemene oxide and its preparation method and use | |
| WO2021047524A1 (en) | Class of functional molecules targeting proteolysis pathways, preparation and application thereof | |
| CN110981865B (en) | Medicine for treating brain glioma and preparation method thereof | |
| CN110590779B (en) | 3, 10 di-p-chlorophenyl 6, 12 diazatetracubane compound, and synthetic method, application and pharmaceutical composition thereof | |
| CN102485735B (en) | 6-fructosamine-4-arylamidoquinazoline derivative and purpose thereof | |
| CN114409563A (en) | Linker for protein labeling and application thereof in biological medicine | |
| CN114437046B (en) | 5-fluorouracil spliced 4-aniline quinazoline compound and preparation method and application thereof | |
| CN107033147B (en) | A kind of bis- target spot inhibitor of BET/HDAC and its preparation method and application | |
| CN114437161B (en) | Zidovudine spliced 4-aniline quinazoline compound and preparation method and application thereof | |
| CN115160234B (en) | Aryl acetate-containing 1,4, 5-trisubstituted imidazole compound, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |